胎儿或胎盘肿瘤相关贫血宫内输血后的围产结局:系统综述
该系统综述纳入43例产前诊断胎儿或胎盘肿瘤合并贫血并接受宫内输血的单胎妊娠,发现其中92.5%存在额外非结构性并发症,围产儿死亡率为25.6%。胎儿水肿或心脏增大与围产儿死亡风险升高相关,而初次宫内输血后血红蛋白较高与风险降低相关;宫内输血作为单一疗法的围产儿死亡率与联合肿瘤消融等治疗无显著差异。
要点
- 产前发现胎儿或胎盘肿瘤合并贫血需宫内输血者,常伴额外非结构性并发症,围产儿死亡率高。
- 胎儿水肿或心脏增大提示围产儿死亡风险增加,初次宫内输血后血红蛋白较高则风险降低。
- 宫内输血作为单一疗法在部分病例中可能合理,但最佳管理策略尚待确定。
核心结论
- 产前诊断胎儿或胎盘肿瘤合并贫血并接受宫内输血的妊娠,围产儿死亡率高达25.6%,与基线胎儿状况严重及产科并发症高发相关。
研究设计与样本
- 纳入标准为产前诊断胎儿或胎盘肿瘤合并贫血并接受宫内输血;排除多胎、合并结构畸形、术中出血所致贫血、非红细胞血制品、产后诊断、终止妊娠及数据不完整者。
关键影像表现/征象
- 初次宫内输血前中位血红蛋白为7.0 g/dL(四分位距6.0-8.8 g/dL)。
- 92.5%的病例在基线存在额外非结构性并发症。
- 40.0%的病例在宫内输血基础上联合了产前肿瘤切除、栓塞或消融。
- 43.2%的病例并发早产、未足月胎膜早破或胎盘早剥,81.1%发生早产。
诊断标准与关键数值
- 围产儿死亡定义为妊娠>22周的宫内胎儿死亡或出生后28天内新生儿死亡。
- 胎儿水肿与围产儿死亡风险升高相关(OR 6.3,95%CI 1.1-37.7,P=0.04)。
- 心脏增大与围产儿死亡风险升高相关(OR 6.3,95%CI 1.1-36.9,P=0.04)。
- 初次宫内输血后血红蛋白较高与围产儿死亡风险降低相关(OR 0.4,95%CI 0.2-0.8,P=0.01)。
临床应用与阅片要点
- 产前发现胎儿或胎盘肿瘤时应评估胎儿贫血及水肿、心脏增大等征象,这些征象提示围产期风险高。
- 宫内输血可作为部分病例的单一疗法,但需结合肿瘤特征及并发症综合决策。
局限性
- 样本量小(43例),来自病例报告和小系列,存在发表偏倚和选择偏倚。
- 仅纳入英文文献,且为回顾性数据,无法确定最佳管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the characteristics and outcomes of pregnancies with a prenatally detected fetal or placental tumor with associated fetal anemia that underwent intrauterine transfusion (IUT).
METHODS: We searched PubMed, EMBASE, Web of Science, Scopus and Google Scholar databases for studies reporting on singleton pregnancies with a prenatally detected fetal or placental tumor complicated by fetal anemia that underwent IUT, published from inception to October 2024. Only articles written in the English language were considered eligible for inclusion. We excluded multiple gestations, fetuses with concomitant structural anomaly, cases that underwent IUT to treat fetal anemia secondary to intraoperative tumor bleeding and cases that received blood products other than red blood cells. Cases in which the tumor was detected postnatally, cases that underwent termination of pregnancy, studies with incomplete data and systematic reviews were also excluded. The primary outcome was perinatal death, defined as intrauterine fetal demise (IUFD) > 22 weeks' gestation or neonatal death within 28 days after birth. Secondary outcomes included IUFD, neonatal death, preterm labor (PTL), preterm prelabor rupture of membranes (PPROM), placental abruption, and spontaneous or medically indicated live preterm birth (PTB). We performed exploratory subgroup analyses, including differences in tumor size according to the presence or absence of additional non-structural complications, as well as differences in baseline characteristics according to perinatal death status and differences in obstetric and perinatal outcomes according to whether the patient underwent prenatal tumor resection, embolization or ablation in addition to IUT.
RESULTS: We included 43 cases in our analysis, including 42 cases from 34 articles identified in the literature search and an additional case managed at our institution. The median hemoglobin level before the initial IUT was 7.0 (interquartile range, 6.0-8.8) g/dL. Most cases (92.5%) had an additional non-structural complication at baseline. Prenatal tumor resection, embolization or ablation was performed as an adjunct to IUT in 40.0% of cases. PTL, PPROM or placental abruption complicated 43.2% of cases. PTB occurred in 81.1% of cases. Perinatal death occurred in 11 (25.6%) cases. We identified a higher likelihood of perinatal death in cases with fetal hydrops (odds ratio (OR), 6.3 (95% CI, 1.1-37.7); P = 0.04) or cardiomegaly (OR, 6.3 (95% CI, 1.1-36.9); P = 0.04), and a lower likelihood of perinatal death was associated with higher fetal hemoglobin after the initial IUT (OR, 0.4 (95% CI, 0.2-0.8), P = 0.01). Perinatal death rates were similar regardless of management strategy (12.5% for IUT as a standalone therapy vs 31.3% for IUT as an adjunct to tumor resection, embolization or ablation; P = 0.1).
CONCLUSION: Pregnancies with a prenatally detected fetal or placental tumor, complicated by fetal anemia that underwent IUT, have a high rate of additional non-structural complications. The rate of perinatal death in this population is high, likely due to the severity of the fetal condition at baseline and high rates of obstetric complications and PTB. IUT as a standalone therapy may be reasonable in selected cases. However, ideal candidates for this approach and the best management strategies remain to be determined. © 2026 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Schenone CV, Fishman SJ, Kim HB, et al. Perinatal outcomes following intrauterine transfusion for fetal anemia secondary to fetal or placental tumor: systematic review. Ultrasound Obstet Gynecol. 2026. PMID: 42070963. doi:10.1002/uog.70234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。